Climbing the blockbuster mountain, Roche/AbbVie team heralds a win in frontline CLL PhIII
AbbVie $ABBV and Roche have posted a goal on their pivotal combination of Venclexta and Gazyva for frontline cases of chronic lymphocytic leukemia, which should help boost their blockbuster dreams for added revenue.
We don’t have the hard data yet, but the companies are already hustling their combo data to regulators in hopes of expanding the market for Venclexta.
In this study their combo beat out Gazyva plus chlorambucil in producing a solid advantage for progression-free survival. That should give the company’s boosters encouragement in believing this drug can push past the $2 billion a year mark toward $3 billion in peak sales — which would make this drug a big contributor to both of their bottom lines.
Venclexta is an apoptosis drug which targets the BCL-2 protein in hopes of encouraging the grim reaper of cancer cells.
Just a few months ago the FDA OK’d the pairing of Venclexta and Rituxan for relapsed CLL, whether or not patients had the 17p deletion mutation, which paved the way to the first approval in 2016.
Both companies see some big upside for this drug, key to their plans to get past generic competition for their big franchise therapies.